FDA Approvals in Oncology: July-September 2025
From July 1 to September 30, 2025, the FDA issued eight new oncology approvals, expanding treatment options for patients...
Tag: Multiple myeloma
From July 1 to September 30, 2025, the FDA issued eight new oncology approvals, expanding treatment options for patients...
This month, the AACR's journals editors highlighted studies on U.S. cancer mortality hotspots, chemotherapy-induced hearing loss, and more.
Multiple myeloma can be tricky to treat, but many treatment options exist, and new research is constantly supporting more.
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
LGBTQ+ cancer survivors offer lessons learned, and a researcher explains the odds of chronic conditions in LGBTQ+ survivors.
Researchers at the Blood Cancer Discovery Symposium presented data on multidrug resistance and clinical trial design.
As the deep reds and yellows of fall leaves give way to twinkling holiday lights, we welcome the new...
How the latest clinical therapies are helping patients and laboratory research informing future treatments.
The word myeloma stems from the Greek word “myelos,” for marrow. Indeed, this type of blood cancer begins in the plasma cells, a type...
Multiple myeloma is a cancer of antibody-producing cells—called plasma cells—that accounts for approximately 1.8 percent of new cancer cases...